drugset / Trial / NCT00480025

GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer

NCT00480025

Phase 3 Terminated 2278 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this clinical trial is to demonstrate the benefit of the immunotherapeutic product GSK1572932A when given to patients with Non-Small Cell Lung Cancer, after removal of their tumor. A course of 13 injections will be administered over 27 months. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

Timeline

Start
2007-10-04
Primary completion
2013-12-06
Completion
2014-09-23

Drugs

EvaluationDrugModalityDoseRoute
Subject GSK1572932A Protein / enzyme biologic Intramuscular